Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07090161 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
A Phase 2 study of Hypertension and Uncontrolled Hypertension, sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT07090161: Recruiting Phase 2 study of Hypertension and Uncontrolled Hypertension, sponsored by Vanda Pharmaceuticals.
NCT07090161 is a Phase 2 study of Hypertension and Uncontrolled Hypertension that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 240 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07090161, a Phase 2 study of Hypertension and Uncontrolled Hypertension, is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
Conditions Studied
Interventions
- DRUG Placebo
- DRUG iloperidone
Study Locations (20)
California
- Vanda Investigative Site - Chula Vista
- Vanda Investigative Site - Dublin
- Vanda Investigative Site - Valencia
- Vanda Investigative Site - Walnut Creek
Arizona
- Vanda Investigative Site - Phoenix
- Vanda Investigative Site - Tempe
- Vanda Investigative Site - Tucson
Florida
- Vanda Investigative Site - Doral
- Vanda Investigative Site - Fort Myers
Illinois
- Vanda Investigative Site - Oak Brook
- Vanda Investigative Site - Tinley Park
Kansas
- Vanda Investigative Site - El Dorado
- Vanda Investigative Site - Wichita
New York
- Vanda Investigative Site - Mount Kisco
- Vanda Investigative Site - Rochester
Georgia
- Vanda Investigative Site - Columbus
Kentucky
- Vanda Investigative Site - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT07090161 shows while recruiting
NCT07090161 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07090161 names 20 study sites across 11 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT07090161 about?
NCT07090161 is a clinical study titled "Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension". A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
What is the current status of trial NCT07090161?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-09-15. Estimated completion is 2026-11.
What conditions does trial NCT07090161 study?
This clinical trial studies the following conditions: Hypertension, Uncontrolled Hypertension.
What interventions are being tested in trial NCT07090161?
The interventions under investigation include: Placebo (DRUG), iloperidone (DRUG).
Who is sponsoring clinical trial NCT07090161?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07090161 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07090161's enrollment target sits among peer trials
240 198th of 470 higher than 271 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI